Consortium Initiates Study of Elotuzumab Combined With Velcade

The Multiple Myeloma Research Consortium (MMRC) is beginning a Phase I/II trial of intravenously administered elotuzumab in combination with Velcade for treating relapsed multiple myeloma.

This study will evaluate the safety and efficacy of the combination in patients who have received one to three prior therapies. Elotuzumab is a humanized monoclonal antibody being developed by PDL BioPharma.
 
The MMRC said the study will be conducted at five of its member institutions.